Sumitomo Pharma Oncology, Inc:News & Media
News & Media
SumitomoDainipponPharmaOncology,Inc.,aclinical-stagepharmaceuticalcompanyfocusedonresearchanddevelopmentfornovelcancertherapeutics,today ...。其他文章還包含有:「AboutUs」、「ClinicalPrograms」、「ContactUs」、「LeadershipTeam」、「MeetOurTeam」、「OurPipeline」、「Publications&Presentations」、「SumitomoPharmaOncology」、「SumitomoPharmaOncology」
查看更多 離開網站About Us
https://oncology.sumitomo-phar
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This ...
Clinical Programs
https://oncology.sumitomo-phar
Discover the science behind our early-stage research compounds in our clinical programs portfolio. Potential therapies include a protein binding inhibitor, ...
Contact Us
https://oncology.sumitomo-phar
Cambridge, MA ... Sumitomo Pharma Oncology, Inc. ... Sumitomo Pharma Oncology, Inc. 84 Waterford Drive Marlborough, MA 01752. Lehi, UT. Sumitomo Pharma Oncology, ...
Leadership Team
https://oncology.sumitomo-phar
Masashi Murata, Ph.D. Chief Strategy Officer Global Strategy and Planning. Read Bio.
Meet Our Team
https://oncology.sumitomo-phar
Hear from people who work at Sumitomo Pharma Oncology and learn the top 10 reasons why people love not just working at SMP Oncology, but making their career ...
Our Pipeline
https://oncology.sumitomo-phar
Discover our pipeline of targeted therapies. Sumitomo Pharma Oncology is advancing cancer treatments for novel pathways in solid tumors and hematologic ...
Publications & Presentations
https://oncology.sumitomo-phar
Explore Sumitomo Pharma Oncology’s publications, abstracts, and presentations which outline ongoing clinical research and pipeline developments.
Sumitomo Pharma Oncology
https://www.linkedin.com
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This ...
Sumitomo Pharma Oncology
https://oncology.sumitomo-phar
Sumitomo Pharma Oncology is a global developer of novel cancer therapeutics dedicated to the promise of purposeful science in oncology.